Search Results

You are looking at 101 - 110 of 521 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

CRE24-040: Gluteal Metastasis of Intrahepatic Cholangiocarcinoma: Clinical Case and Literature Review

Natalia de la Puente Mota, Yolanda Gómez Fandiño, Francisco Javier Anguita Ramos, María López López, Mariaclaudia Ocharán Puell, Beatriz Carnero López, Jorge González Ramírez, Adriana Fernández García, and José Conde Vales

diagnosed with intrahepatic cholangiocarcinoma three years prior and was treated with resection and adjuvant therapy involving chemotherapy and radiotherapy. He was referred to the general surgery outpatient clinic by his oncologist for the excision of a

Full access

Highlights of the NCCN Oncology Research Program

unresectable) colorectal cancer who have received prior treatment with a fluoropyrimidine (5-FU or capecitabine) and oxaliplatin or who have experienced a recurrence within 12 months of adjuvant therapy with a regimen that included oxaliplatin. For study

Full access

HSR20-102: Quality Outcomes in Colon Cancer

Michelle Moskal and Neeharika S. Makani

, only 6.3% of high risk stage II and 45.5% of stage III patients received adjuvant therapy. Data showed 100% compliance with initiation of adjuvant 5-FU based chemotherapy within 12 weeks post surgery, which is recommended in high risk stage II and III

Full access

BPI20-014: Clinical Pathway and Education Implementation to Support Guideline Adherent Breast Cancer Care for Rural Women Under Age 50

Robin M. Lally, Elizabeth Reed, and Roksana Zak

-treatment assessments, consultations, considerations, neoadjuvant and adjuvant therapy and survivorship care. Oncology provider survey return rate was 25%. Results indicated satisfaction but changes needed to pathway design and content. Modified pathways were

Full access

University of Michigan Comprehensive Cancer Center Opportunities for Improvement Project

Tara M. Breslin, Marcy Waldinger, and Samuel M. Silver

Center Educational Forum attendees illustrated a theme related to adjuvant therapy delay. Providers were surprised to learn that as many as 10% of patients were not recorded as receiving adjuvant endocrine therapy. Performance on this measure did not

Full access

Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now?

Rosalyn A. Juergens and Julie R. Brahmer

. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer . Eastern Cooperative Oncology Group . N Engl J Med 2000 ; 343 : 1217 – 1222 . 20. Mineo TC Ambrogi V

Full access

Role of Radiotherapy in the Management of Merkel Cell Carcinoma of the Skin

Roy H. Decker and Lynn D. Wilson

the addition of adjuvant therapy . J Clin Oncol 2005 ; 23 : 7236 – 7237 . 13. Wilson LD Gruber SB . Merkel cell carcinoma and the controversial role of adjuvant radiation therapy: clinical choices in the absence of statistical evidence

Full access

The Current Status of Combined Radiotherapy and Chemotherapy for Locally Advanced or Resected Pancreas Cancer

Mary F. Mulcahy, Andrew O. Wahl, and William Small Jr.

1990 ; 66 : 56 – 61 . 7 Whittington R Bryer MP Haller DG . Adjuvant therapy of resected adenocarcinoma of the pancreas . Int J Radiat Oncol Biol Phys 1991 ; 21 : 1137 – 1143 . 8 Abrams RA . Adjuvant therapy for pancreatic

Full access

NCCN Guidelines Insights: Colon Cancer, Version 2.2018

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Ignacio Garrido-Laguna, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, and Deborah A. Freedman-Cass

, adjuvant chemotherapy. 10 Population and institutional studies have shown that adjuvant therapy may confer a survival advantage in some patients with resected colon cancer (eg, those with stage III or high-risk stage II disease). 11 – 14 Furthermore

Full access

NCCN Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019

Featured Updates to the NCCN Guidelines

Margaret A. Tempero, Mokenge P. Malafa, E. Gabriela Chiorean, Brian Czito, Courtney Scaife, Amol K. Narang, Christos Fountzilas, Brian M. Wolpin, Mahmoud Al-Hawary, Horacio Asbun, Stephen W. Behrman, Al B. Benson III, Ellen Binder, Dana B. Cardin, Charles Cha, Vincent Chung, Mary Dillhoff, Efrat Dotan, Cristina R. Ferrone, George Fisher, Jeffrey Hardacre, William G. Hawkins, Andrew H. Ko, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Eileen M. O’Reilly, Jorge Obando, Sushanth Reddy, Sarah Thayer, Robert A. Wolff, Jennifer L. Burns, and Griselda Zuccarino-Catania

only approximately half of patients with potentially curative resections receive adjuvant therapy due to issues associated with postoperative complications, recovery, and performance status. 9 Median survival for patients with resected tumors under